Publikationer Kurt Boman i internationella tidskrifter

 

Almroth H, Hoglund N, Boman K, Englund A, Jensen S, Kjellman B, Tornvall P, Rosenqvist M. Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study. Eur Heart J. 2009 Apr;30(7):827-33.
Andersson J, Johansson L, Ladenvall P, Wiklund PG, Stegmayr B, Jern C, Boman K. C-Reactive Protein Is a Determinant of First-Ever Stroke: Prospective Nested Case-Referent Study. Cerebrovasc Dis. 2009 Apr 24;27(6):544-51.
Chinali M, Aurigemma GP, de Simone G, Mishra RK, Gerdts E, Wachtell K, Boman K, Dahlof B, Devereux RB. Mitral E wave deceleration time to peak E velocity ratio and cardiovascular outcome in hypertensive patients during antihypertensive treatment (from the LIFE echo-substudy). Am J Cardiol. 2009 Oct 15;104(8):1098-104.
Hagnelius NO, Boman K, Nilsson TK. Fibrinolysis and von Willebrand factor in Alzheimer's disease and vascular dementia - a case-referent study. Thromb Res. 2009 Oct 28.
Holme I, Boman K, Brudi P, Egstrup K, Gohlke-Barwolf C, Kesaniemi VA, Malbecq W, Rossebo AB, Wachtell K, Willenheimer R, Pedersen TR. Observed and predicted reduction of ischaemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial. Eur Heart J submitted. 2009.
Remmets J, Boman K, Olofsson M. How many systolic and diastolic echocardiographic variables do we have do measure? - an exploratory study in elderly patients. European Journal of Heart Failure, submitted. 2009.
Stenlund H, Lonnberg G, Jenkins P, Norberg M, Persson M, Messner T, Boman K, Pearson T, Wall S, Nystrom L, Weinehall L. Fewer deaths from cardiovascular disease than expected from the Systematic Coronary Risk Evaluation chart in a Swedish population. Eur J Cardiovasc Prev Rehabil. 2009 Jun;16(3):321-4.
Wennberg P, Wensley F, Johansson L, Boman K, Angelantonio ED, Rumley A, Lowe G, Hallmans G, Jansson JH. Reduced risk of myocardial infarction related to active commuting: inflammatory and haemostatic effects are potential major mediating mechanisms. Eur J Cardiovasc Prev Rehabil. 2009 Oct 8.
Lofgren C, Boman K, Olofsson M, Lindholm L. Is cardiac consultation with remote-controlled real-time echocardiography a wise use of resources? Telemed J E Health. 2009 Jun;15(5):431-8.
Olofsson M, Boman K. Usefulness of natriuretic peptides in primary health care - an explorative study in elderly patients. Scand J Prim Care Submitted. 2009
Thogersen AM, Nilsson TK, Weinehall L, Boman K, Eliasson M, Hallmans G, et al. Changes in plasma C-reactive protein and hemostatic factors prior to and after a first myocardial infarction with a median follow-up time of 8 years. Blood Coagul Fibrinolysis. 2009 Jul;20(5):340-6.
Andersson J, Johansson L, Ladenvall P, Wiklund PG, Stegmayr B, Jern C, Boman K. C-Reactive Protein Is a Determinant of First-Ever Stroke: Prospective Nested Case-Referent Study. Cerebrovasc Dis. 2009 Apr 24;27(6):544-51.
Boman K, Jansson JH, Nilsson T, Swedberg K, Cleland JG, Poole-Wilson P. Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure - a COMET substudy. Thromb Res. 2009 Sep 15.
Boman K, Hernestal Boman J, Andersson J, Olofsson M, Dahlof B. Effects on atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy. Clinical and Applied Thrombosis/Hemostasis. 2009.
Fhärm E, Rolandsson O, Svensson M, Boman K. Is there an appropriate focus on coronary heart disease in patients with newly diagnosed type 2 diabetes? Diabetic medicin (DME-2009-00613). 2009.
Gronlund H, Hallmans G, Jansson JH, Boman K, Wikstrom M, de Faire U, et al. Low levels of IgM antibodies against phosphorylcholine predict development of acute myocardial infarction in a population-based cohort from northern Sweden. Eur J Cardiovasc Prev Rehabil. 2009 Jun;16(3):382-6.
Boman K, Olofsson M, Forsberg J, Boström SÅ. Remote-controlled robotic arm for real-time echocardiography: the diagnostic future for patients in rural areas. Telemedicine and e-Health. 2009;15(2):1-6.
Boman K, Gerdts E, Wachtell K, Dahlof B, Nieminen MS, Olofsson M, Papademetriou V, Devereux RB. Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study. Eur J Cardiovasc Prev Rehabil. 2009 Apr;16(2):242-8.
Lind M, Boman K, Johansson L, Nilsson TK, Ohlin AK, Birgander LS, et al. Thrombomodulin as a marker for bleeding complications during warfarin treatment. Arch Intern Med. 2009 Jul 13;169(13):1210-5.
Sahli D, Eriksson JW, Boman K, Svensson MK. Tissue plasminogen activator (tPA) activity is a novel and early marker of asymptomatic LEAD in type 2 diabetes. Thrombosis Research. 2009;123:701-6.
 
Norberg EB, Boman K, Lofgren B. Activities of daily living for old persons in primary health care with chronic heart failure. Scand J Caring Sci. 2008 Jun;22(2):203-10.
Cicala S, de Simone G, Wachtell K, Gerdts E, Boman K, Nieminen MS, et al. Clinical impact of 'in-treatment' wall motion abnormalities in hypertensive patients with left ventricular hypertrophy: the LIFE study. J Hypertens. 2008 Apr;26(4):806-12.
Hagglund L, Boman K, Lundman B, Brulin C. Depression among elderly people with and without heart failure, managed in a primary healthcare setting. Scand J Caring Sci. 2008 Sep;22(3):376-82.
Andersson J, Boman K, Jansson JH, Nilsson TK, Lindahl B. Effect of intensive lifestyle intervention on C-reactive protein in subjects with impaired glucose tolerance and obesity. Results from a randomized controlled trial with 5-year follow-up. Biomarkers. 2008 Nov;13(7):671-9.
Hagglund L, Boman K, Lundman B. The experience of fatigue among elderly women with chronic heart failure. Eur J Cardiovasc Nurs. 2008 Feb 8.
Gerdts E, Okin P, de Simone G, Cramariuc D, Wachtell K, Boman K, et al. Gender differences in left ventricular structure and function during antihypertensive treatment. The Losartan Intervention For Endpoint reduction in hypertension study. Hypertension. 2008;51:TBD (E-pub 8 February 2008).
Eriksson M, Johnson O, Boman K, Hallmans G, Hellsten G, Nilsson TK, et al. Improved fibrinolytic activity during exercise may be an effect of the adipocyte-derived hormones leptin and adiponectin. Thromb Res. 2008;122(5):701-8.
Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008 Sep 25;359(13):1343-56.
Chinali M, De Simone G, Wachtell K, Gerdts E, Gardin JM, Boman K, et al. Left atrial systolic force in hypertensive patients with left ventricular hypertrophy: the LIFE study. Journal of Hypertension. 2008.
Eriksson MA, Rask E, Johnson O, Carlstrom K, Ahren B, Eliasson M, Boman K, Soderberg S. Sex-related differences in the associations between hyperleptinemia, insulin resistance and dysfibrinolysis. Blood Coagul Fibrinolysis. 2008 Oct;19(7):625-32.
Sahli D, Eriksson JW, Boman K, Svensson MK. Tissue plasminogen activator (tPA) activity is a novel and early marker of asymptomatic LEAD in type 2 diabetes. Thromb Res. 2008 Oct 20.
 
Olofsson M, Edebro D, Boman K. Are elderly patients with suspected HF misdiagnosed? A primary health care center study. Cardiology. 2007;107(4):226-32.
Brannstrom M, Ekman I, Boman K, Strandberg G. Being a close relative of a person with severe, chronic heart failure in palliative advanced home care - a comfort but also a strain. Scand J Caring Sci. 2007 Sep;21(3):338-44.
Rossebo AB, Pedersen TR, Allen C, Boman K, Chambers J, Egstrup K, et al. Design and Baseline Characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Study. Am J Cardiol. 2007 Apr 1;99(7):970-3.
Cicala S, Devereux RB, de Simone G, Wachtell K, Gerdts E, Boman K, et al. Electrocardiographic and Echocardiographic Detection of Myocardial Infarction in Patients with Left-Ventricular Hypertrophy The LIFE Study. Am J Hypertens. 2007 Jul;20(7):771-6.
Palmieri V, Okin PM, Simone GD, Bella JN, Wachtell K, Gerdts E, Boman K, Nieminen MS, Dahlof B, Devereux RB. Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study. J Hypertens. 2007 May;25(5):1079-85.
Wanhainen A, Nilsson TK, Bergqvist D, Boman K, Bjorck M. Elevated tissue plasminogen activator in patients with screening-detected abdominal aortic aneurysm. J Vasc Surg. 2007 Jun;45(6):1109-13.
Hagglund L, Boman K, Olofsson M, Brulin C. Fatigue and health-related quality of life in elderly patients with and without heart failure in primary healthcare. Eur J Cardiovasc Nurs. 2007 Sep;6(3):208-15.
Nilsson JB, Boman K, Jansson JH, Nilsson T, Naslund U. The influence of acute-phase levels of haemostatic factors on reperfusion and mortality in patients with acute myocardial infarction treated with streptokinase. J Thromb Thrombolysis. 2007 Aug 25.
Gerdts E, Wachtell K, Omvik P, Otterstad JE, Oikarinen L, Boman K, et al. Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial. Hypertension. 2007 Feb;49(2):311-6.
Brannstrom M, Ekman I, Boman K, Strandberg G. Narratives of a man with severe chronic heart failure and his wife in palliative advanced home care over a 4.5-year period. Contemp Nurse. 2007 Dec;27(2):10-22.
Wennberg P, Eliasson M, Hallmans G, Johansson L, Boman K, Jansson JH. The risk of myocardial infarction and sudden cardiac death amongst snuff users with or without a previous history of smoking. J Intern Med. 2007 Sep;262(3):360-7.
Rantapaa-Dahlqvist S, Boman K, Tarkowski A, Hallmans G. Up regulation of monocyte chemoattractant protein-1 expression in anti-citrulline antibody and immunoglobulin M rheumatoid factor positive subjects precedes onset of inflammatory response and development of overt rheumatoid arthritis. Ann Rheum Dis. 2007 Jan;66(1):121-3.
 
Ekman I, Andersson G, Boman K, Charlesworth A, Cleland JG, Poole-Wilson P, et al. Adherence and perception of medication in patients with chronic heart failure during a five-year randomised trial. Patient Educ Couns. 2006 Jun;61(3):348-53.
Olofsson M, Edebro D, Boman K. Are elderly patients with suspected HF misdiagnosed? A primary health care center study. Cardiology. 2006;107(4):226-32.
Narayan P, Papademetriou V, Wachtell K, Gerdts E, Boman K, Nieminen MS, et al. Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension Study. Hypertension. 2006 May;47(5):868-73.
Norberg M, Stenlund H, Lindahl B, Boman K, Weinehall L. Contribution of Swedish moist snuff to the metabolic syndrome: a wolf in sheep's clothing? Scand J Public Health. 2006;34(6):576-83.
Wennberg P, Lindahl B, Hallmans G, Messner T, Weinehall L, Johansson L, Boman K, Jansson JH. The effects of commuting activity and occupational and leisure time physical activity on risk of myocardial infarction. Eur J Cardiovasc Prev Rehabil. 2006 Dec;13(6):924-30.
Palmieri V, Okin PM, Bella JN, Wachtell K, Oikarinen L, Gerdts E, Boman K, Nieminen MS, Dahlof B, Devereux RB. Electrocardiographic strain pattern and left ventricular diastolic function in hypertensive patients with left ventricular hypertrophy: the LIFE study. J Hypertens. 2006 Oct;24(10):2079-84.
Hagglund L, Boman K, Olofsson M, Brulin C. Fatigue and health-related quality of life in elderly patients with and without heart failure in primary healthcare. Eur J Cardiovasc Nurs. 2006 Nov 6.
Brannstrom M, Ekman I, Norberg A, Boman K, Strandberg G. Living with severe chronic heart failure in palliative advanced home care. Eur J Cardiovasc Nurs. 2006 Dec;5(4):295-302.
 
Ekman I, Andersson G, Boman K, Charlesworth A, Cleland JG, Poole-Wilson P, et al. Adherence and perception of medication in patients with chronic heart failure during a five-year randomised trial. Patient Educ Couns. 2005 Aug 30.
Brannstrom M, Brulin C, Norberg A, Boman K, Strandberg G. Being a palliative nurse for persons with severe congestive heart failure in advanced homecare. Eur J Cardiovasc Nurs. 2005 Jun 7;4(4):314-23.
Nilsson TK, Boman K, Jansson JH, Thogersen AM, Berggren M, Broberg A, et al. Comparison of soluble thrombomodulin, von Willebrand factor, tPA/PAI-1 complex, and high-sensitivity CRP concentrations in serum, EDTA plasma, citrated plasma, and acidified citrated plasma (Stabilyte) stored at -70 degrees C for 8-11 years. Thromb Res. 2005;116(3):249-54.
Ekman I, Boman K, Olofsson M, Aires N, Swedberg K. Gender makes a difference in the description of dyspnoea in patients with chronic heart failure. Eur J Cardiovasc Nurs. 2005 Jun;4(2):117-21.
Oldgren J, Fellenius C, Boman K, Jansson JH, Nilsson TK, Wallentin L, et al. Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease. J Intern Med. 2005 Nov;258(5):420-7.
Boman K, Olofsson M, Dahlof B, Gerdts E, Nieminen MS, Papademetriou V, et al. Left ventricular structure and function in sedentary and physically active subjects with left ventricular hypertrophy (the LIFE Study). Am J Cardiol. 2005 Jan 15;95(2):280-3.
Wanhainen A, Bergqvist D, Boman K, Nilsson TK, Rutegård J, Björck M. Risk factors associated with abdominal aortic aneurysm: A population-based study with historical and current data. J Vasc Surg. 2005;41:390-6.
 
Olsen MH, Wachtell K, Bella JN, Liu JE, Boman K, Gerdts E, et al. Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy). Am J Cardiol. 2004 Oct 15;94(8):1076-80.
Warensjo E, Jansson JH, Berglund L, Boman K, Ahren B, Weinehall L, et al. Estimated intake of milk fat is negatively associated with cardiovascular risk factors and does not increase the risk of a first acute myocardial infarction. A prospective case-control study. Br J Nutr. 2004 Apr;91(4):635-42.
Johansson L, Jansson JH, Stegmayr B, Nilsson TK, Hallmans G, Boman K. Hemostatic factors as risk markers for intracerebral hemorrhage: a prospective incident case-referent study. Stroke. 2004 Apr;35(4):826-30.
Kontos J, Papademetriou V, Wachtell K, Palmieri V, Liu JE, Gerdts E, Boman K, Nieminen MS, Dahlof B, Devereux RB. Impact of valvular regurgitation on left ventricular geometry and function in hypertensive patients with left ventricular hypertrophy: the LIFE study. J Hum Hypertens. 2004 Jun;18(6):431-6.
Thogersen AM, Soderberg S, Jansson JH, Dahlen G, Boman K, Nilsson TK, et al. Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction. Eur J Cardiovasc Prev Rehabil. 2004 Feb;11(1):33-40.
Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004 Nov 17;292(19):2350-6.
Devereux RB, Dahlof B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 2004 Sep 14;110(11):1456-62.

Aurigemma GP, Devereux RB, Wachtell K, Palmieri V, Boman K, Gerdts E, et al. Left ventricular mass regression in the LIFE study: effect of previous antihypertensive treatment. Am J Hypertens. 2003 Mar;16(3):180-6.
Jansson JH, Boman K, Messner T. Trends in blood pressure, lipids, lipoproteins and glucose metabolism in the Northern Sweden MONICA project 1986-99. Scand J Public Health. 2003;Suppl 61:43-50.

Wachtell K, Dahlof B, Rokkedal J, Papademetriou V, Nieminen MS, Smith G, Gerdts E, Boman K, Bella JN, Devereux RB. Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Am Heart J. 2002 Dec;144(6):1057-64.
Gerdts E, Oikarinen L, Palmieri V, Otterstad JE, Wachtell K, Boman K, et al. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Hypertension. 2002 Mar 1;39(3):739-43.
Gerdts E, Papademetriou V, Palmieri V, Boman K, Bjornstad H, Wachtell K, et al. Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study). Am J Cardiol. 2002 Feb 15;89(4):399-402.
Nilsson JB, Nilsson TK, Jansson JH, Boman K, Soderberg S, Naslund U. The effect of streptokinase neutralizing antibodies on fibrinolytic activity and reperfusion following streptokinase treatment in acute myocardial infarction. J Intern Med. 2002 Nov;252(5):405-11.
Weinehall L, Ohgren B, Persson M, Stegmayr B, Boman K, Hallmans G, et al. High remaining risk in poorly treated hypertension: the 'rule of halves' still exists. J Hypertens. 2002 Oct;20(10):2081-8.
Boman KO, Jansson JH, Nyhlen KA, Nilsson TK. Improved fibrinolysis after one year of treatment with enalapril in men and women with uncomplicated myocardial infarction. Thromb Haemost. 2002 Feb;87(2):311-6.
Cline CM, Boman K, Holst M, Erhardt LR. The management of heart failure in Sweden. Eur J Heart Fail. 2002 Jun;4(3):373-6.
Devereux RB, Palmieri V, Liu JE, Wachtell K, Bella JN, Boman K, et al. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. J Hypertens. 2002 Jul;20(7):1445-50.
Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G. Prospective study on soluble thrombomodulin and von Willebrand factor and the risk of ischemic and hemorrhagic stroke. Thromb Haemost. 2002 Feb;87(2):211-7.
Nilsson TK, Spence JD, Nilsson PM, Eliasson M, Jansson JH, Boman K. Quantitative measurement of carotid atherosclerosis in relation to levels of von Willebrand factor and fibrinolytic variables in plasma--a 2-year follow-up study. J Cardiovasc Risk. 2002 Aug;9(4):215-21.
Bella JN, Wachtell K, Boman K, Palmieri V, Papademetriou V, Gerdts E, et al. Relation of left ventricular geometry and function to aortic root dilatation in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Am J Cardiol. 2002 Feb 1;89(3):337-41.
Ladenvall P, Johansson L, Jansson JH, Jern S, Nilsson TK, Tjarnlund A, Jern C, Boman K. Tissue-type plasminogen activator -7,351C/T enhancer polymorphism is associated with a first myocardial infarction. Thromb Haemost. 2002;87(1):105-9.

Devereux RB, Bella J, Boman K, Gerdts E, Nieminen MS, Rokkedal J, et al. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Blood Press. 2001;10(2):74-82.
Thogersen AM, Nilsson TK, Dahlen G, Jansson JH, Boman K, Huhtasaari F, et al. Homozygosity for the C677-->T mutation of 5,10-methylenetetrahydrofolate reductase and total plasma homocyst(e) ine are not associated with greater than normal risk of a first myocardial infarction in northern Sweden. Coron Artery Dis. 2001 Mar;12(2):85-90.
Johansson A, Boman K, Cederquist K, Forsberg H, Olsson T. Increased levels of tPA antigen and tPA/PAI-1 complex in myotonic dystrophy. J Intern Med. 2001 Jun;249(6):503-10.
Wanhainen A, Bjorck M, Boman K, Rutegard J, Bergqvist D. Influence of diagnostic criteria on the prevalence of abdominal aortic aneurysm. J Vasc Surg. 2001;34(2):229-35.

Weinehall L, Boman K, Hallmans G, Hellsten G. Effects of a community-based program on risk factors for cardiovascular disease. The Västerbotten Intervention Project 1985-2000. Scand J Clin Lab Invest. 2000.
Devereux RB, Roman MJ, Palmieri V, Okin PM, Boman K, Gerdts E, et al. Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension. J Hypertens. 2000;18(8):1129-38.
Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke. 2000 Jan;31(1):26-32.
Ohgren B, Weinehall L, Stegmayr B, Boman K, Hallmans G, Wall S. What else adds to hypertension in predicting stroke? An incident case- referent study. J Intern Med. 2000;248(6):475-82.

Lindholm L, Hallgren CG, Boman K, Markgren K, Weinehall L, Ogren JE. Cost-effectiveness analysis with defined budget: how to distribute resources for the prevention of cardiovascular disease? Health Policy. 1999;48(3):155-70.
Weinehall L, Westman G, Hellsten G, Boman K, Hallmans G, Pearson TA, et al. Shifting the distribution of risk: results of a community intervention in a Swedish programme for the prevention of cardiovascular disease. J Epidemiol Community Health. 1999;53(4):243-50.

Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation. 1998 Nov 24;98(21):2241-7.
Bylesjo I, Boman K. Is diabetes mellitus an advantage in patients with acute intermittent porphyria. Eur J Intern Med. 1998;9:203-5.
Weinehall L, Johnson O, Jansson JH, Boman K, Huhtasaari F, Hallmans G, et al. Perceived health modifies the effect of biomedical risk factors in the prediction of acute myocardial infarction. An incident case-control study from northern Sweden. J Intern Med. 1998 Feb;243(2):99-107.

Jansson JH, Boman K, Brannstrom M, Nilsson TK. High concentration of thrombomodulin in plasma is associated with hemorrhage: a prospective study in patients receiving long-term anticoagulant treatment. Circulation. 1997;96(9):2938-43.
A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group. Eur Heart J. 1997 Sep;18(9):1416-25.
Nilsson JB, Nilsson TK, Naslund U, Jansson JH, Boman K. Relationship between fibrinolytic activity following streptokinase treatment in acute myocardial infarction and vectorcardiographic signs of reperfusion. Fibrinol and proteol. 1997;11(4):193-99.

Nilsson TK, Thogersen AM, Jansson JH, Boman K. Comparison of von Willebrand factor and tissue plasminogen activator concentrations in plasma and serum. Clin Chem. 1996 Jun;42(6 Pt 1):976-7.
Jonsson B, Johannesson M, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J. 1996 Jul;17(7):1001-7.
Bylesjo I, Forsgren L, Lithner F, Boman K. Epidemiology and clinical characteristics of seizures in patients with acute intermittent porphyria. Epilepsia. 1996;37(3):230-5.
Jansson JH, Boman K, Brannstrom M, Nilsson TK. Increased levels of plasma thrombomodulin are associated with vascular and all-cause mortality in patients on long-term anticoagulant treatment. Eur Heart J. 1996;17(10):1503-5.
Bylesjo EI, Boman K, Wetterberg L. Obesity treated with phototherapy: four case studies. Int J Eat Disord. 1996;20(4):443-46.
Gustafson T, Boman K, Rosenhall L, Sandstrom T, Wester PO. Skeletal muscle magnesium and potassium in asthmatics treated with oral beta 2-agonists. Eur Respir J. 1996;9(2):237-40.
Wikström L, Steen L, Holmgren G, Bjerle P, Boman K. Treatment of orthostatic hypotension with L-THREO-DOPS in Swedish patients with familial amyloidotic polyneuropathy FAP-met30. An open pilot study. Amyloid. 1996;3:162-66.

Boman K, Saetre H, Karlsson LG, Ritter B, Marsell R, Wingman H, et al. Antianginal effect of conventional and controlled release diltiazem in stable angina pectoris. Eur J Clin Pharmacol. 1995;49(1-2):27-30.
Brannstrom M, Jansson JH, Boman K, Nilsson TK. Endothelial haemostatic factors may be associated with mortality in patients on long-term anticoagulant treatment. Thromb Haemost. 1995;74(2):612-5.
Jansson JH, Westman G, Boman K, Nilsson T, Norberg B. Oral anticoagulant treatment in a medical care district--a descriptive study. Scand J Prim Health Care. 1995;13(4):268-74.
Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics. Lancet. 1995 Aug 5;346(8971):329-36.

Boman K, Hellsten G, Bruce A, Hallmans G, Nilsson TK. Endurance physical activity, diet and fibrinolysis. Atherosclerosis. 1994;106(1):65-74.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994 Nov 19;344(8934):1383-9.
Nilsson TK, Boman K, Bjerle P, Hallmans G, Hellsten G. von Willebrand factor and fibrinolytic variables are differently affected in the insulin resistance syndrome. J Intern Med. 1994;235(5):419-23.

Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. Am J Cardiol. 1993 Feb 15;71(5):393-400.
Hellsten G, Boman K, Saarem K, Hallmans G, Nilsson TK. Effects on fibrinolytic activity of corn oil and a fish oil preparation enriched with omega-3-polyunsaturated fatty acids in a long-term study. Curr Med Res Opin. 1993;13(3):133-9.
Jansson JH, Boman K, Nilsson TK. Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction. Eur J Clin Pharmacol. 1993;44(5):485-8.
Treatment of atrial fibrillation. Recommendations from a workshop arranged by the Medical Products Agency (Uppsala, Sweden) and the Swedish Society of Cardiology. Eur Heart J. 1993 Oct;14(10):1427-33.

Herlitz J. Comparison of lisinopril versus digoxin for congestive heart failure during maintenance diuretic therapy. The Lisinopril-Digoxin Study Group. Am J Cardiol. 1992 Oct 8;70(10):84C-90C.
Hellsten G, Boman K, Bjerle P, Blom P, Nilsson TK. Increased plasminogen activator inhibitor and tissue plasminogen activator levels in subjects with electrocardiographic abnormality indicative of ischaemic heart disease: a cross-sectional study in Norsjo, Sweden. Eur Heart J. 1992;13(1):57-60.

Olofsson BO, Grankvist K, Olsson T, Boman K, Forsberg K, Lafvas I, et al. Assessment of hypothalamic-pituitary function in patients with familial amyloidotic polyneuropathy. J Intern Med. 1991;229(1):55-9.
Jansson JH, Johansson B, Boman K, Nilsson TK. Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol. Eur J Clin Pharmacol. 1991;40(4):321-6.
Jansson JH, Johansson B, Boman K, Nilsson TK. Hypo-fibrinolysis in patients with hypertension and elevated cholesterol. J Intern Med. 1991;229(4):309-16.
Stalhammar J, Bergman U, Boman K, Dahlen M. Metabolic control in diabetic subjects in three Swedish areas with high, medium, and low sales of antidiabetic drugs. Diabetes Care. 1991;14(1):12-9.

Gustafson T, Boman K, Hentschel J, Moberg E, Wester PO. Effects of peroral magnesium on electrolytes and ventricular premature beats in patients with cardiac failure on diuretic treatment. Magnesium-Bulletin. 1990;12:106-11.
Olofsson BO, Granqvist K, Boman K. Evaluation of the anaemia in familial amyloidotic polyneuropathy. Eur J of Int Med. 1990;1:425-9.
Olofsson BO, Grankvist K, Boman K, Forsberg K, Lafvas I, Lithner F. Assessment of thyroid and adrenal function in patients with familial amyloidotic polyneuropathy. J Intern Med. 1989;225(5):337-41.

Boman K, Eriksson P, Slunga L. Is addition of prazosin beneficial in chronic heart failure refractory to angiotensin converting enzyme inhibition? Eur J Clin Pharmacol. 1989;37(4):431-2.
Hellsten G, Boman K, Hallmans G, Dahlen G. Lipids and endurance physical activity. Atherosclerosis. 1989;75(1):93-4.

Olofsson BO, Backman C, Boman K. Echocardiographic assessment of the course of the heart disease in familial amyloidotic polyneuropathy. Am J of Noninvasive Cardiology. 1988;2:300-05.
Boman K, Weinehall L, Ogren JE. Management of digitalis therapy in a primary care area. Scand J Prim Health Care. 1988 Nov;6(4):195-8.
Multicenter trial of hemodilution in acute ischemic stroke. Results of subgroup analyses. Scandinavian Stroke Study Group. Stroke. 1988 Apr;19(4):464-71.

Jansson JH, Eriksson P, Boman K, Eriksson S, Olofsson BO, Sjogren B. Cardiac stimulation threshold in familial amyloidosis with polyneuropathy. Pacing Clin Electrophysiol. 1987 Jul;10(4 Pt 1):817-21.
Multicenter trial of hemodilution in acute ischemic stroke. I. Results in the total patient population. Scandinavian Stroke Study Group. Stroke (4S). 1987 Jul-Aug;18(4):691-9.

Eriksson P, Boman K, Jacobsson B, Olofsson BO. Cardiac arrhythmias in familial amyloid polyneuropathy during anaesthesia. Acta Anaesthesiol Scand. 1986;30(4):317-20.

Multicenter trial of hemodilution in ischemic stroke--background and study protocol. Scandinavian Stroke Study Group (4S). Stroke. 1985 Sep-Oct;16(5):885-90.

Boman K. Digitalis intoxication in geriatric in-patients. A prospective clinical study of the value of serum digitalis concentration measurement. Acta Med Scand. 1983;214(5):345-51.
Boman K. Digoxin and the geriatric in-patient. A randomized trial of digoxin versus placebo. Acta Med Scand. 1983;214(5):353-60.
The effect of pindolol on the two years mortality after complicated myocardial infarction. Eur Heart J. 1983 Jun;4(6):367-75.
Boman K, Mollerberg H, Ogren JE. What do patients know about their digitalis? A comparison between two different areas in Sweden. Ups J Med Sci. 1983;88(2):141-9.

Boman K, Allgulander S, Skoglund M. Is maintenance digoxin necessary in geriatric patients? Acta Med Scand. 1981;210(6):493-5.

Weinehall L, Westman G, Hellsten G, Boman K, Hallmans G, Wall S. Educational screening in primary health care strengthens the effect of a Swedish community intervention program for the prevention of cardiovascular disease.
Nadal M, Boman K. Impaired circadian rhythm of vasopressin in chronic heart failure and in healthy subjects treated with oral furosemide. J of Int Med.In manuscript.
Weinehall L, Boman K, Hallmans G, Asplund K, Wall S. Prevention reduces the health gap. A ten year evalution of a Swedish community intervension program for the prevention of CVD.
Boman K, Hellsten G, Bjorck M, Ohgren JE, Nordenstam I. Sales of cardiovascular and antidiabetic drugs in relation to a community-based intervension programme for cardiovascular diseases and diabetes.
Pehrson K, Boman K, Dahlstrom U, Edvardsson N, Persson S. The validity of the diagnostic assessment of congestive heart failure in primary health care.
Boman K. Withdrawal of digoxin in geriatrics patients. A retrospective long-term follow-up study.

Stöd vår forskning redan idag

Så hjälper du till

Stiftelsen vill inspirera och stödja yngre men även äldre läkare, sjuksköterskor, apotekare med flera till att forska inom områdena medicin och omvårdnad inom Skellefteå sjukvård (kommunerna Skellefteå och Norsjö).

Postgiro & Bankgiro

Stöd vår verksamhet genom att sätta in pengar på följande Post- och Bankgiro:

Stiftelsens postgiro 444 81 29-9
Stiftelsens bankgiro 710-9721
Stiftelsens swish 1233351574

Dela vår hemsida

Hjälp vår stiftelse och våra forskare genom att sprida vår sida vidare via sociala medier.
Information om cookies